About Frontier Medicines
Frontier Medicines is a company based in San Francisco (United States) founded in 2018 by Roberto Zoncu, Daniel Nomura, and Chris Varma.. Frontier Medicines has raised $235.5 million across 3 funding rounds from investors including GLPG, RA Capital and Driehaus. The company has 115 employees as of December 31, 2023. Frontier Medicines offers products and services including The Frontier™ Platform, AutoTAC™ Platform, and Precision Pipeline. Frontier Medicines operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter San Francisco, United States
- Employees 115 as on 31 Dec, 2023
- Founders Roberto Zoncu, Daniel Nomura, Chris Varma
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Frontier Medicines Corporation
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$235.5 M (USD)
in 3 rounds
-
Latest Funding Round
$80 M (USD), Series C
Feb 22, 2024
-
Investors
GLPG
& 11 more
-
Employee Count
115
as on Dec 31, 2023
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Frontier Medicines
Frontier Medicines offers a comprehensive portfolio of products and services, including The Frontier™ Platform, AutoTAC™ Platform, and Precision Pipeline. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Proprietary system using chemoproteomics and machine learning for medicine development.
Technology for targeted degradation of disease-causing proteins.
Pipeline focused on precision-based medicines for specific patient groups.
Unlock access to complete
Unlock access to complete
Funding Insights of Frontier Medicines
Frontier Medicines has successfully raised a total of $235.5M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $80 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $80.0M
-
First Round
First Round
(18 Apr 2019)
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2024 | Amount | Series C - Frontier Medicines | Valuation | Deerfield , Droia Ventures | |
| Jun, 2021 | Amount | Series B - Frontier Medicines | Valuation | Woodline Partners , RA Capital Management | |
| Apr, 2019 | Amount | Series A - Frontier Medicines | Valuation | Deerfield , Droia |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Frontier Medicines
Frontier Medicines has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include GLPG, RA Capital and Driehaus. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Founded Year | Domain | Location | |
|
Droia Ventures is focused on investing in drug development companies.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on multiple sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Frontier Medicines
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Frontier Medicines
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Frontier Medicines Comparisons
Competitors of Frontier Medicines
Frontier Medicines operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Frontier Medicines
Frequently Asked Questions about Frontier Medicines
When was Frontier Medicines founded?
Frontier Medicines was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Where is Frontier Medicines located?
Frontier Medicines is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of Frontier Medicines?
Chris Varma is the current CEO of Frontier Medicines. They have also founded this company.
Is Frontier Medicines a funded company?
Frontier Medicines is a funded company, having raised a total of $235.5M across 3 funding rounds to date. The company's 1st funding round was a Series A of $67M, raised on Apr 18, 2019.
How many employees does Frontier Medicines have?
As of Dec 31, 2023, the latest employee count at Frontier Medicines is 115.
What does Frontier Medicines do?
Developer of a bioinformatics platform for drug development and chemoproteomics. The proprietary chemoproteomics platform uses machine learning technology to analyze proteins to identify active binding sites as drug targets to treat diseases. The platform consists of a database of hotspots in proteins, a library of chemically diverse compounds, and a novel approach to protein degradation. It ofefrs a lead program FMC-376, which is a novel dual inhibitor of both active and inactive KRASG12 for non-small cell lung, colorectal, and pancreatic cancers.
Who are the top competitors of Frontier Medicines?
Frontier Medicines's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does Frontier Medicines offer?
Frontier Medicines offers The Frontier™ Platform, AutoTAC™ Platform, and Precision Pipeline.
Who are Frontier Medicines's investors?
Frontier Medicines has 12 investors. Key investors include GLPG, RA Capital, Driehaus, ArrowMark Partners, and Deerfield.